DUBLIN – Cellectis SA is supplying its transcription activator-like effector nuclease (Talen) genome editing technology to what has been billed as the first "grand-scale community-wide project" of the Genome Project Write (GP-Write) initiative, an effort to develop a cell line that is resistant to naturally occurring viruses.